Suven Life Sciences: The financial results for the period ended September 30, 2026
Suven Life Sciences (SUVEN) filed a disclosure titled "The financial results for the period ended September 30, 2026". The company is valued at about ₹7,381 crore.
What happened
Suven Life Sciences (SUVEN) filed a disclosure with the exchanges on 5 November 2026 at 01:29 PM titled "The financial results for the period ended September 30, 2026".
Company snapshot
Suven Life Sciences is a small-cap company in the Healthcare sector, with a market value of about ₹7,381 crore.
The stock last traded at ₹261.2, against a 52-week range of ₹124.1–₹403.4 (35.2% below the high).
Before this filing the shares had moved −15.3% over the month and −15.7% over three months. Average daily turnover over the last 20 sessions was about ₹18.96 crore.
Promoters held 65.47% at the end of Q2 FY27, down 4.61% points from the previous quarter. Foreign institutions owned 0.48% and domestic institutions 2.73%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 2 | -51.5 | -2.36 |
| Q2 FY26 | 1 | -77.3 | -3.48 |
| Q3 FY26 | 3 | -101.9 | -4.55 |
| Q4 FY26 | 2 | -45.6 | -2.02 |
| Q1 FY27 | 4 | -127.6 | -4.84 |
What history shows
BCEIE's records show 2 previous results filings from the company since May 2026.
Across 300 similar disclosures by other Healthcare companies, shares moved +1.4% on average the next day and +2.0% over five days; 58% of them rose the next day.
Market-wide, 10,790 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 42% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- Management commentary, margins and order book or guidance in the investor presentation.
- 5 November 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.